

<b><i>Acinetobacter baumannii</i> clonal complex</b> (n=3,189 from 66 Hospitals)			
	<b>Susceptibility (Range)</b>	<b>Number of Isolates</b>	<b>Number of Hospitals</b>
<b>Ampicillin-Sulbactam</b>	-	-	-
<b>Piperacillin-Tazobactam</b>	33.3% (0-81%)	1,873	41
<b>Ceftriaxone</b>	11.3% (0-61%)	1,475	29
<b>Ceftazidime</b>	30.2% (2-100%)	2,184	42
<b>Cefepime</b>	33.8% (3-82%)	1,864	35
<b>Imipenem</b>	-	-	-
<b>Meropenem</b>	52.9% (15-100%)	1,561	34
<b>Amikacin</b>	43.2% (0-80%)	2,004	36
<b>Gentamicin</b>	40.8% (10-100%)	2,970	62
<b>Tobramycin</b>	46.1% (14-100%)	2,126	46
<b>Ciprofloxacin/Levofloxacin</b>	32.7% (3-100%)	3,024	62
<b>TMP-SMX</b>	48.8% (18-84%)	2,859	59

**Comments from LA County Healthcare-Associated Infection and Antibiotic Resistance Committee:**

Insufficient data were available for ampicillin-sulbactam and minocycline which might be useful for some strains of *Acinetobacter baumannii*.